Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Haystack Oncology | 2022 | Series A | $56.0M | Baltimore |
| Matchpoint Therapeutics | 2022 | Series A | $70.0M | Cambridge |
| Novome Biotechnologies | 2022 | Series B | $43.5M | South San Francisco |
| Ozette Technologies | 2022 | Series A | $26.0M | Seattle |
| DEM BioPharma | 2022 | Series A | $70.0M | Cambridge |
| Cardea Bio | 2022 | Grant | $1.1M | San Diego |
| Pheast Therapeutics | 2022 | Series A | $76.0M | Palo Alto |
| Affini-T Therapeutics | 2022 | Series Unknown | $175.0M | Watertown |
| Creyon Bio | 2022 | Series A | $40.0M | San Diego |
| Ambys Medicines | 2021 | Series A | $47.0M | South San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 126 | Haystack Oncology | Series A | $56.0M | Baltimore, United States |
| 127 | Matchpoint Therapeutics | Series A | $70.0M | Cambridge, United States |
| 128 | Novome Biotechnologies | Series B | $43.5M | South San Francisco, United States |
| 129 | Ozette Technologies | Series A | $26.0M | Seattle, United States |
| 130 | DEM BioPharma | Series A | $70.0M | Cambridge, United States |
| 131 | Cardea Bio | Grant | $1.1M | San Diego, United States |
| 132 | Pheast Therapeutics | Series A | $76.0M | Palo Alto, United States |
| 133 | Affini-T Therapeutics | Series Unknown | $175.0M | Watertown, United States |
| 134 | Creyon Bio | Series A | $40.0M | San Diego, United States |
| 135 | Ambys Medicines | Series A | $47.0M | South San Francisco, United States |
Haystack Oncology enables precision oncology to optimize treatment strategies.
Matchpoint Therapeutics is a biotechnology company that integrates chemoproteomics, ML, and covalent chemistry to treat serious illnesses.
Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.
Ozette Technologies is a life science data company that accelerates the development of therapies and diagnostics by digitizing immune data.
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.
Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
NextVivo is a biotech company developing an immune organoid technology platform.
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
Industrial-scale genome sequencing
Crop Enhancement develop sustainable agrochemical formulations that employ environmentally friendly chemistry to improve crop yields.
IpiNovyx Bio is a biopharmaceutical company developing immunoproteasome-modulating therapeutics to treat autoimmune diseases.
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients.
Mnemo Therapeutics specializes in biotechnology and life science.
Soteria is a biotechnology company that develops immunotherapies to treat cancer patients
SeQure Dx provides safety data for on and off-target CRISPR gene editing therapies
Rheostat Therapeutics is a bio therapeutics company.
Magnolia NeuroSciences discovers and develops drug-like small molecule therapeutics for the prevention of neuronal cell death.
Genetron Health is a world-leading expert in precision medicine.
Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.
Alexandria Venture Investments has invested in 157 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Therapeutics, Health Care, Life Science, Medical. The firm invests across 26 different industry categories.
Among tracked funding rounds, Affini-T Therapeutics received $175.0M in a Series Unknown round. Alexandria Venture Investments's total known invested capital is $3.8B.
Alexandria Venture Investments's average investment size is $37.7M across its portfolio of 157 companies.
Recent Alexandria Venture Investments portfolio additions include Haystack Oncology, Matchpoint Therapeutics, Novome Biotechnologies, Ozette Technologies, DEM BioPharma. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors